Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
617.80 | 4,994 Cr | 26.80 | 4.62 | 0.16 | 16.86 | 22.47 | 15.40 | ||
123.30 | 4,673 Cr | -14.93 | 0.00 | 0.00 | 77.47 | -181.73 | -83.09 | ||
1308.90 | 4,426 Cr | -60.50 | 5.96 | 0.06 | -19.58 | -9.69 | -11.97 | ||
728.05 | 4,134 Cr | 31.46 | 4.05 | 0.00 | 12.19 | 13.06 | 7.83 | ||
914.00 | 4,131 Cr | 41.10 | 5.08 | 0.00 | 10.70 | 12.41 | 7.98 | ||
389.80 | 3,819 Cr | 39.42 | 5.24 | 0.09 | 11.57 | 12.36 | 6.82 | ||
333.05 | 3,600 Cr | 76.04 | 13.61 | 0.20 | 18.26 | 19.25 | 12.68 | ||
| Median: 7 Co. | — | 617.80 | 4,134 Cr | 31.46 | 5.08 | 0.06 | 12.19 | 12.41 | 7.83 |
Zota Health Care Ltd (ZOTA) is currently trading at 1,313.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zota Health Care Limited is an Indian pharmaceutical and retail healthcare company operating a manufacturing/export arm and Davaindia, a rapidly scaled private-label generic pharmacy chain that markets medicinal, OTC and ayurvedic products with a strong focus on chronic therapies and affordability across its COCO and FOFO store formats. Davaindia has become the principal growth engine, contributing roughly 76–80% of revenue in 9MFY26, with 2,331 active stores as of December 2025 and aggressive quarterly additions (276 stores in Q3FY26) that drove consolidated revenue of ₹14,295.14 lakhs in Q3FY26, reflecting ~98% year-on-year growth. Unit economics show promising store-level profitability: mature COCO stores report ~60%-67% gross margin and management targets 25%–30% EBITDA at mature COCO stores, but rapid expansion and pre-opening costs compressed consolidated EBITDA to ₹127.58 lakhs in Q3FY26 and generated a consolidated PAT loss due to elevated employee and setup expenses. The company strengthened its balance sheet via a completed ₹350 crore QIP to fund COCO rollout, working capital, and general corporate purposes, while pursuing backward integration and product expansion through acquisitions and Everyday Herbal Group ownership to boost OTC and private-label margins. Zota leverages technology and supply‑chain design—cloud-based software and AI tools for real-time operations—plus a cluster-based hyperlocal fulfilment model and a central Surat warehousing hub, which collectively aim to improve inventory turns, reduce distribution intermediaries and sustain competitive pricing advantage.
Over the past 52 weeks, Zota Health Care Ltd has traded between a low of ₹794.95 and a high of ₹1,740.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zota Health Care Ltd has a market capitalization of approximately 4,425.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zota Health Care Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -60.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,425.50 Cr, Zota Health Care Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zota Health Care Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zota Health Care Ltd is -60.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Zota Health Care Limited is an Indian pharmaceutical and retail healthcare company operating a manufacturing/export arm and Davaindia, a rapidly scaled private-label generic pharmacy chain that markets medicinal, OTC and ayurvedic products with a strong focus on chronic therapies and affordability across its COCO and FOFO store formats.
Davaindia has become the principal growth engine, contributing roughly 76–80% of revenue in 9MFY26, with 2,331 active stores as of December 2025 and aggressive quarterly additions (276 stores in Q3FY26) that drove consolidated revenue of ₹14,295.14 lakhs in Q3FY26, reflecting ~98% year-on-year growth.
Unit economics show promising store-level profitability: mature COCO stores report ~60%-67% gross margin and management targets 25%–30% EBITDA at mature COCO stores, but rapid expansion and pre-opening costs compressed consolidated EBITDA to ₹127.58 lakhs in Q3FY26 and generated a consolidated PAT loss due to elevated employee and setup expenses.
The company strengthened its balance sheet via a completed ₹350 crore QIP to fund COCO rollout, working capital, and general corporate purposes, while pursuing backward integration and product expansion through acquisitions and Everyday Herbal Group ownership to boost OTC and private-label margins.
Zota leverages technology and supply‑chain design—cloud-based software and AI tools for real-time operations—plus a cluster-based hyperlocal fulfilment model and a central Surat warehousing hub, which collectively aim to improve inventory turns, reduce distribution intermediaries and sustain competitive pricing advantage.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,426 Cr
High Risk
-60.5
32.2
—
6.0
1,740.00
794.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
6
Neutral
4
Bullish
4
Bearish
17
Neutral
4
Bullish
25
Bearish
11
Neutral
0
Bullish
21
